BiotechTube

Sublingual film containing Dexmedetomidine (BXCL501) + Placebo Film

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Agitation Associated With Bipolar Disorder

Conditions

Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder

Trial Timeline

Feb 24, 2020 → May 21, 2020

NCT ID
NCT04276883

About Sublingual film containing Dexmedetomidine (BXCL501) + Placebo Film

Sublingual film containing Dexmedetomidine (BXCL501) + Placebo Film is a phase 3 stage product being developed by BioXcel Therapeutics for Agitation Associated With Bipolar Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04276883. Target conditions include Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder.

What happened to similar drugs?

2 of 13 similar drugs in Agitation Associated With Bipolar Disorder were approved

Approved (2) Terminated (2) Active (9)
✅Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
✅Dexmedetomidine + Lorazepam 2 MG/MLBioXcel TherapeuticsApproved
🔄Brexpiprazole, OPC-34712LundbeckPhase 3
🔄Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
🔄BrexpiprazoleLundbeckPhase 3
🔄AXS-05 (dextromethorphan-bupropion) + PlaceboAxsome TherapeuticsPhase 3
❌AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04276883Phase 3Completed
NCT04268303Phase 3Completed

Competing Products

20 competing products in Agitation Associated With Bipolar Disorder

See all competitors
ProductCompanyStageHype Score
ONO-2020 + PlaceboOno PharmaceuticalPhase 2
42
Quetiapine + Haloperidol + Lorazepam + CogentinAstraZenecaApproved
43
Brexpiprazole, OPC-34712LundbeckPhase 3
37
Brexpiprazole, OPC-34712 + Placebo Oral TabletLundbeckPhase 3
37
BrexpiprazoleLundbeckPhase 3
37
AXS-05 (dextromethorphan-bupropion) + PlaceboAxsome TherapeuticsPhase 3
37
AXS-05 + Bupropion + PlaceboAxsome TherapeuticsPhase 2/3
35
AXS-05 (dextromethorphan-bupropion)Axsome TherapeuticsPhase 3
29
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
AXS-05 + PlaceboAxsome TherapeuticsPhase 3
37
Pimavanserin 34 mg + Pimavanserin 20 mgAcadia PharmaceuticalsPhase 2
24
PimavanserinAcadia PharmaceuticalsPhase 2
32
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
22
Sublingual film containing BXCL501 (Dexmedetomidine) + Placebo filmBioXcel TherapeuticsPhase 1
19
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
BXCL501 + Matching PlaceboBioXcel TherapeuticsPhase 3
30
Sublingual film containing dexmedetomidine (BXCL501) + Placebo FilmBioXcel TherapeuticsPhase 3
30
BXCL501 + BXCL501 + Placebo filmBioXcel TherapeuticsPhase 2
17
BXCL501 + Placebo filmBioXcel TherapeuticsPhase 2
17
Sublingual film containing Dexmedetomidine + Sublingual Placebo FilmBioXcel TherapeuticsPhase 1/2
22